Sustained efficacy was observed for aquaporin-4-IgG-seropositive (AQP4-IgG+) NMOSD in the open-label extension period of a Phase 3 study.
Presence and number of cortical lesions at MS diagnosis predicted development of secondary progressive MS and disability accumulation in a 20-year study.
Preliminary trial data showed that the drug was generally well tolerated and drove sustained disability improvement in a significant proportion of patients [1].
A randomised double-blind controlled pilot trial demonstrated patient benefits of melatonin in MS patients. Sleep disturbances and fatigue may be alleviated by this supplement.
Bio-naïve and bio-experienced patients with moderately to severely active UC achieved more clinical remission when treated with filgotinib over placebo at weeks 10 and 58.
Upadacitinib outperformed placebo at all primary and secondary endpoints evaluating maintenance therapy for patients with moderately to severely active ulcerative colitis.
Clinical remission was sustained throughout the 52-week FORTIFY maintenance study for patients with Crohn’s Disease who responded well to risankizumab induction therapy.
Ethnic or religion-based forms of discrimination against trained medical specialists and the influence of National Socialism in neurology were topics of focus at the DGN 2021.
A treat-to-target strategy of ustekinumab in CD patients could maintain a proportion of patients in endoscopic response in a long-term extension of a phase 3 trial.
The ASTIClite trial, developed to analyse the efficacy of haematopoietic stem cell transplantation on refractory Crohn’s disease patients, was halted due to unexpected serious events.
One click to optimal prevention, diagnosis and therapy: The German Fraunhofer Institutes present the first prototype of a digital patient model as part of the MED²ICIN lead project.
The Satelia platform combines algorithms and people. The result is that many hospitalisations are avoided.
The American College of Physicians has announced that it is partnering with YouTube to create educational content to combat misinformation about Covid-19 treatment and vaccines.
Ritlecitinib and brepocitinib showed significant benefits over placebo at 8 weeks of the 32-week, phase 2b, VIBRATO trial in moderate to severe active ulcerative colitis.
This question was addressed in at the Ludwig Maximilian University Clinic for Psychiatry and Psychotherapy, in the context of the global Mental Health Week.
In moderately to severely active ulcerative colitis patients, symptoms control was reached significantly more for upadacitinib over placebo patients after 2 weeks.
Dupilumab showed maintained patient benefits for eosinophilic oesophagitis. The 28-week phase 3 trial showed sustained symptomatic, histologic, and endoscopic benefits.
The administration of ZED-1227 demonstrated clinical and histological efficacy in coeliac disease, a first effective therapy for these patients in a phase 2a trial.
Maintained efficacy of tofacitinib was observed for a substantial proportion of ulcerative colitis (UC) patients in the OCTAVE open-label extension study.
Interview with Dr. Giuliano Piccoliori, physician in South Tyrol and scientific head of the Institute of General Medicine and Public Health in Bolzano on the current situation and future of general medicine.